Contribution of quantitative I-123-ioflupane SPECT/CT to the differential diagnosis of dementia with lewy bodies
Quantitative I-123-ioflupane uptake assessment using SUV measures offers clinically relevant diagnostic value for differentiating DLB from other neurodegenerative diseases. It also helps in identifying patients with visual hallucinations, supporting the broader integration of SUV-based dopaminergic imaging into clinical workflows.
Authors
- George Prashanth Kurian (ORCID: https://orcid.org/0000-0001-8398-7194)
- Paolo Salvioni Chiabotti (ORCID: https://orcid.org/0000-0002-6745-0722)
- Mario Jreige (ORCID: https://orcid.org/0000-0003-3918-150X)
- John Olivier Prior (ORCID: https://orcid.org/0000-0003-1429-1374)
- Adrien Depeursinge (ORCID: https://orcid.org/0000-0002-2362-0304)
- Marie Nicod Lalonde (ORCID: https://orcid.org/0000-0002-4886-0611)
- Gilles Allali (ORCID: https://orcid.org/0000-0002-4455-6719)
- Niklaus Schaefer (ORCID: https://orcid.org/0000-0002-9732-7696)
- Noemie Lejay
- Jérémy Perriraz
- Olivier Rouaud (ORCID: https://orcid.org/0000-0001-9767-8421)
- Caroline Hall
Institutions
- HES-SO Valais-Wallis (CH)
- University of Lausanne (CH)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1007/s00259-025-07680-7
- Primary Topic
- Neurological and metabolic disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00